Sebastian Gallo-Bernal

Dr. Sebastian Gallo-Bernal

Massachusetts General Hospital - Harvard Medical School, Boston, USA
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Jose Cornejo, Ph.D.Jose Cornejo, Ph.D.
Jose Cornejo, Ph.D.
JCJorge Cornejo
Jorge Cornejo
MVMariela Vargas
Mariela Vargas
CHCarlos G. Helguero
Carlos G. Helguero
RARafhael Milanezi de Andrade
Rafhael Milanezi de Andrade
Thais RussomanoThais Russomano
Thais Russomano
Three‐dimensional printing (3DP) has recently gained importance in the medical industry, especially in surgical specialties. It uses different techniques and materials based on patients’ needs, which allows bioprofessionals to design and develop unique pieces using medical imaging provided by computed tomography (CT) and magnetic resonance imaging (MRI). Therefore, the Department of Biology and Medicine and the Department of Physics and Engineering, at the Bioastronautics and Space Mechatronics Research Group, have managed and supervised an international cooperation study, in order to present a general review of the innovative surgical applications, focused on anatomical systems, such as the nervous and craniofacial system, cardiovascular system, digestive system, genitourinary system, and musculoskeletal system. Finally, the integration with augmented, mixed, virtual reality is analyzed to show the advantages of personalized treatments, taking into account the improvements for preoperative, intraoperative planning, and medical training. Also, this article explores the creation of devices and tools for space surgery to get better outcomes under changing gravity conditions.

16 November 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
GMGermán J. Medina-Rincón
Germán J. Medina-Rincón
SGSebastian Gallo-Bernal
Sebastian Gallo-Bernal
PJPaula Andrea Jiménez
Paula Andrea Jiménez
LSLissa Cruz Savedra
Lissa Cruz Savedra
JRJuan David Ramírez
Juan David Ramírez
HMHéctor M. Medina
Héctor M. Medina
Chronic manifestations of Chagas disease present as disabling and life-threatening conditions affecting mainly the cardiovascular and gastrointestinal systems. Although meaningful research has outlined the different molecular mechanisms underlying Trypanosoma cruzi’s infection and the host-parasite interactions that follow, prompt diagnosis and treatment remain a challenge, particularly in developing countries and also in those where the disease is considered non-endemic. This review intends to present an up-to-date review of the parasite’s life cycle, genetic diversity, virulence factors, and infective mechanisms, as well as the epidemiology, clinical presentation, diagnosis, and treatment options of the main chronic complications of Chagas disease.

22 April 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
Antonia PinoAntonia Pino
Antonia Pino
GMGermán J. Medina-Rincón
Germán J. Medina-Rincón
SGSebastian Gallo-Bernal
Sebastian Gallo-Bernal
ADAlejandro Duran-Crane
Alejandro Duran-Crane
ÁDÁlvaro Ignacio Arango Duque
Álvaro Ignacio Arango Duque
HMHector M. Medina
Hector M. Medina
Despite nearly a century of research and accounting for the highest disease burden of any parasitic disease in the Western Hemisphere, Chagas disease (CD) is still a challenging diagnosis, primarily due to its poor recognition outside of Latin America. Although initially considered endemic to Central and South America, globalization, urbanization, and increased migration have spread the disease worldwide in the last few years, making it a significant public health threat. The international medical community’s apparent lack of interest in this disease that was previously thought to be geographically restricted has delayed research on the complex host–parasite relationship that determines myocardial involvement and its differential behavior from other forms of cardiomyopathy, particularly regarding treatment strategies. Multiple cellular and molecular mechanisms that contribute to degenerative, inflammatory, and fibrotic myocardial responses have been identified and warrant further research to expand the therapeutic arsenal and impact the high burden attributed to CD. Altogether, cardiac dysautonomia, microvascular disturbances, parasite-mediated myocardial damage, and chronic immune-mediated injury are responsible for the disease’s clinical manifestations, ranging from asymptomatic disease to severe cardiac and gastrointestinal involvement. It is crucial for healthcare workers to better understand CD transmission and disease dynamics, including its behavior on both its acute and chronic phases, to make adequate and evidence-based decisions regarding the disease. This review aims to summarize the most recent information on the epidemiology, pathogenesis, clinical presentation, diagnosis, screening, and treatment of CD, emphasizing on Chagasic cardiomyopathy’s (Ch-CMP) clinical presentation and pathobiological mechanisms leading to sudden cardiac death.

28 July 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
SGSebastian Gallo-Bernal
Sebastian Gallo-Bernal
NPNasly Patino-Jaramillo
Nasly Patino-Jaramillo
CCCamilo A. Calixto
Camilo A. Calixto
SHSergio A. Higuera
Sergio A. Higuera
JFJulian F. Forero
Julian F. Forero
HMHector M. Medina
Hector M. Medina
Gadolinium-enhanced cardiac magnetic resonance has revolutionized cardiac imaging in the last two decades and has emerged as an essential and powerful tool for the characterization and treatment guidance of a wide range of cardiovascular diseases. However, due to the high prevalence of chronic renal dysfunction in patients with cardiovascular conditions, the risk of nephrogenic systemic fibrosis (NSF) after gadolinium exposure has been a permanent concern. Even though the newer macrocyclic agents have proven to be much safer in patients with chronic kidney disease and end-stage renal failure, clinicians must fully understand the clinical characteristics and risk factors of this devastating pathology and maintain a high degree of suspicion to prevent and recognize it. This review aimed to summarize the existing evidence regarding the physiopathology, clinical manifestations, diagnosis, and prevention of NSF related to the use of gadolinium-based contrast agents.

29 October 2024 in Pediatric Radiology
Verified
Journal Article
Closed access
PDF file
SGSebastian Gallo-Bernal
Sebastian Gallo-Bernal
VPValeria Peña-Trujillo
Valeria Peña-Trujillo
MGMichael S. Gee
Michael S. Gee

17 February 2020 in Cardiology in the Young
Verified
Journal Article
Closed access
PDF file
VHVíctor M. Huertas-Quiñones
Víctor M. Huertas-Quiñones
CMCamilo F. Mestra
Camilo F. Mestra
VPValeria Peña-Trujillo
Valeria Peña-Trujillo
SGSebastian Gallo-Bernal
Sebastian Gallo-Bernal
MVMariana Villaveces
Mariana Villaveces
LALaura C. Alarcón-Forero
Laura C. Alarcón-Forero
Background: Although multiple studies have been conducted in the adult population, there is a vast knowledge gap regarding the epidemiologic characteristics of cardiomyopathies in the paediatric population. This issue is even more crucial when the precarious situation of medical research in Latin America is considered. Given the potential impact that these disorders could have on Latin American health systems, a comprehensive epidemiologic study regarding the clinical profile and sociodemographic characteristics of these patients will influence the way we approach paediatric cardiomyopathies.Methods: An observational retrospective study was conducted at a tertiary referral centre for Colombian and Latin American paediatric cardiology. We analysed all cases of primary cardiomyopathies in children younger than 18 years of age who presented at our institution between 2010 and 2016. Cases of cardiomyopathies were classified according to World Health Organization guidelines.Results: From a total of 29,533 children who attended our institution during the study period, 89 new cases of primary cardiomyopathies were identified. The median age at diagnosis was 11 years (interquartile range 4–9). Dilated cardiomyopathy accounted for 57.3% (n = 51) of cases; hypertrophic cardiomyopathy, 12.3% (n = 11); restrictive cardiomyopathy, 8.9% (n = 8); non-compacted cardiomyopathy, 7.8% (n = 7); arrhythmogenic ventricular cardiomyopathy, 6.7% (n = 6); and unspecified cardiomyopathy, 6.7% (n = 6). Heart failure was observed in 53.93% of the patients. The overall mortality was 12.36% (n = 11), which included two of eight patients who underwent cardiac transplantation.